XLO SCHEDULE 13G: SEC filing

Logos Global Management LP and affiliated entities

Filed with the SEC on · accession 0000935836-26-000612

XLO filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 16, 2026. Logos Global Management LP and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 730,315 shares of Xilio Therapeutics (9.99%), consisting of pre-funded warrants and Series A Warrants subject to a 9.99% ownership cap. The stock moved -3.6% by the first close after the filing.

Summary of the filing

Logos Global Management LP and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 730,315 shares of Xilio Therapeutics (9.99%), consisting of pre-funded warrants and Series A Warrants subject to a 9.99% ownership cap. The filing is a passive investment disclosure, not indicating intent to influence control.

Key details

Shares of Common Stock beneficially owned (via warrants)$730K
Pre-funded warrants to acquire Common Stock$476K
Series A Warrants to acquire Common Stock$476K
IssuerXilio Therapeutics, Inc.
Reporting person / investment adviserLogos Global Management LP
General partner of logos globalLogos Global Management GP LLC
Reporting person / fund holding securitiesLogos Opportunities Fund IV LP
General partner of opportunities fundLogos Opportunities IV GP LLC
Managing partner, logos global management lp; control personArsani William
Portfolio manager, logos opportunities fund iv lpGraham Walmsley

How XLO stock reacted

Close before

$7.99

Nov 13, 2026

First close after

-3.63%

$7.70

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for XLO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for XLO?

Click here

Frequently asked questions

What did XLO file with the SEC on Nov 16, 2026?

XLO filed a SCHEDULE 13G (SEC filing). Logos Global Management LP and affiliated entities filed a Schedule 13G disclosing beneficial ownership of 730,315 shares of Xilio Therapeutics (9.99%), consisting of pre-funded warrants and Series A Warrants subject to a 9.99% ownership cap. The filing is a passive investment disclosure, not indicating intent to influence control.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did XLO stock react to this filing?

XLO closed at $7.99 before the filing and $7.70 on Nov 16, 2026 (-3.63%).

Other XLO SEC filings

Get alerts when XLO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days